Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4300-4305

  Stephenson, Andrew J ^a   Kattan, Michael W ^a   Eastham, James A ^a   Bianco Jr , Fernando J ^a   Yossepowitch, Ofer ^a   Vickers, Andrew J ^a   Klein, Eric A ^a   Wood, David P ^a   Scardino, Peter T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CLINICAL FEATURE; COHORT ANALYSIS; GLEASON SCORE; HUMAN; LETHALITY; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; TREATMENT OUTCOME; VALIDATION PROCESS; CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSTATE TUMOR; UNITED STATES;

AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 70349313376     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.2501     Document Type: Article

References (36)

1. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005
2. Cuzick J, Fisher G, Kattan MW, et al: Longterm outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186-1194, 2006
3. Johansson JE, Andren O, Andersson SO, et al: Natural history of early, localized prostate cancer. JAMA 291:2713-2719, 2004
4. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005
5. Draisma G, Boer R, Otto SJ, et al: Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878, 2003
6. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
7. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
8. Blumberg JW: PDA applications for physicians. ASCO News 16:S4-S6, 2004
9. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431-440, 1989
10. Bianco FJ Jr, Scardino PT, Eastham JA: Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function ("trifecta" ). Urology 66:83-94, 2005
11. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. JASA 94:496-509, 1999
12. Harrell FE Jr, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 247: 2543-2546, 1982
13. Albertsen PC, Hanley JA, Barrows GH, et al: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248-1253, 2005
14. Kupelian PA, Elshaikh M, Reddy CA, et al: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20:3376-3385, 2002
15. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003
16. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994
17. Porter CR, Kodama K, Gibbons RP, et al: 25-year prostate cancer control and survival outcomes: A 40-year radical prostatectomy single institution series. J Urol 176:569-574, 2006
18. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001
19. Harlan SR, Cooperberg MR, Elkin EP, et al: Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 170:1804-1807, 2003
20. Carter CA, Donahue T, Sun L, et al: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21:4001-4008, 2003
21. Klotz L: Active surveillance for prostate cancer: For whom? J Clin Oncol 23:8165-8169, 2005
22. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
23. Thompson IM Jr, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296:2329-2335, 2006
24. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
25. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
26. Thompson IM, Tangen C, Basler J, et al: Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168: 1008-1012, 2002
27. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004
28. Carter HB, Ferrucci L, Kettermann A, et al: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-1527, 2006
29. Pinsky PF, Andriole G, Crawford ED, et al: Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 109:1689-1695, 2007
30. Ulmert D, Serio AM, O'Brien MF, et al: Longterm prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 26:835-841, 2008
31. Etzioni RD, Ankerst DP, Weiss NS, et al: Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 99:1510-1515, 2007
32. Amling CL, Riffenburgh RH, Sun L, et al: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22: 439-445, 2004
33. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638, 2003
34. Stephenson AJ, Scardino PT, Eastham JA, et al: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98:715-717, 2006
35. Vickers AJ, Bianco FJ, Serio AM, et al: The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 99: 1171-1177, 2007
36. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 358:1250-1261, 2008